Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.76 |
| ▸ | GLA | P06280 | 2/20 | 0.97 |
| ▸ | GAA | P10253 | 2/20 | 0.97 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.97 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.97 |
| ▸ | MMP1 | P03956 | 1/20 | 0.97 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | ACHE | P22303 | 1/20 | 0.97 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.97 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | HPGD | P15428 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.96 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL1780951 | 0.99 | GLA (0.96) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4164613 | 0.99 | GLA (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL29356918 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL12313065 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL29367581 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL131381 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4034 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL13420262 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL19534323 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL663859 | 0.98 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190015423-A1 | REGULATION OF GENE EXPRESSION BY MODULATING PRIMARY CILIA LENGTH | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-01-17 | — | — | US | claimed |
| EP-4684836-A2 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | Oryzon Genomics, S.A. (ES) | 2026-01-28 | — | — | EP | disclosed |
| EP-3429571-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | ORYZON GENOMICS SA (ES) | 2025-10-08 | — | — | EP | disclosed |
| US-12435156-B2 | Methods for treating neuroblastoma with combination therapy | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250228937-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | TORAY INDUSTRIES, INC. (JP) | 2025-07-17 | — | — | US | disclosed |
| CN-118453852-A | AMHRII-binding compounds for preventing or treating cancer | 埃克塞里艾克西斯公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2024148339-A1 | USE OF A MULTIMERIC ANTI-DR5 ANTIBODY FOR TREATING CANCER | IGM BIOSCIENCES, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-12031977-B2 | Ex vivo system for determining multiple drug-drug transporter interactions and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| CN-110891970-B | AMHRII-binding compounds for preventing or treating cancer | 埃克塞里艾克西斯公司 | 2024-05-10 | — | — | CN | disclosed |
| EP-4360649-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2024-05-01 | — | — | EP | disclosed |
| CN-102911197-B | Camptothecin silicone hybrid derivative, composition containing camptothecin silicone hybrid derivative and application thereof | HANGZHOU HAIHANG BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO LTD | 2015-05-06 | — | — | CN | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| US-8883737-B2 | Methods of treating cancer | ENDOCYTE, INC. (IN) | 2014-11-11 | — | — | US | disclosed |
| US-20130330326-A1 | METHODS OF TREATING CANCER | ENDOCYTE, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| EP-2638395-A1 | METHODS OF TREATING CANCER | Endocyte, Inc. (US) | 2013-09-18 | — | — | EP | disclosed |
| CN-103282777-A | Methods of treating cancer | ENDOCYTE INC | 2013-09-04 | — | — | CN | disclosed |
| CN-102911197-A | Camptothecin silicone hybrid derivative, composition containing camptothecin silicone hybrid derivative and application thereof | HANGZHOU HAIHANG BIOLOG MEDICAL TECHNOLOGY CO LTD | 2013-02-06 | — | — | CN | disclosed |
| WO-2012065085-A1 | METHODS OF TREATING CANCER | ENDOCYTE, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435156-B2 | Methods for treating neuroblastoma with combination therapy | GMFG, CD22, CD47 | TOP1 1154/4885GLA 294/4885GAA 349/4885 |
| US-20130330326-A1 | METHODS OF TREATING CANCER | FOLR2, FOLR1, FOLH1 | TOP1 7/4885GLA 968/4885GAA 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.